Article Text

PDF
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis
  1. Young Ho Lee1,
  2. Gwan Gyu Song2
  1. 1Division of Rheumatology, Korea University Medical Center, Seoul, South Korea
  2. 2Department of Rheumatology, College of Medicine, Korea University, Seoul, South Korea
  1. Correspondence to Professor Young Ho Lee, Division of Rheumatology, Korea University Medical Center, Seoul 02841, Republic of Korea; lyhcgh{at}korea.ac.kr

Statistics from Altmetric.com

We have read with interest the article by Nakaoka and colleagues1 on the efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis. The authors have presented a randomised controlled trial in which they suggest a preference for tocilizumab over placebo for time to relapse of Takayasu arteritis, without any new safety concerns. We would like to draw attention to a few points in this regard.

First, Takayasu arteritis and giant cell arteritis share some similarities in terms of …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles